Maxim Group Reaffirms “Buy” Rating for Soligenix Inc (SNGX)

Maxim Group reissued their buy rating on shares of Soligenix Inc (OTC:SNGX) in a research note released on Friday morning, reports. They currently have a $35.00 target price on the stock.

Soligenix (OTC:SNGX) opened at 2.37 on Friday. The company’s market cap is $12.97 million. The firm has a 50-day moving average of $2.86 and a 200-day moving average of $2.86. Soligenix has a 52 week low of $2.31 and a 52 week high of $14.40.

COPYRIGHT VIOLATION WARNING: This article was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at

Soligenix Company Profile

Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Stock Target Prices

What are top analysts saying about Soligenix Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Soligenix Inc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit